Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Coherus Oncology (CHRS) Interest Expenses (2016 - 2025)

Coherus Oncology's Interest Expenses history spans 12 years, with the latest figure at $2.2 million for Q4 2025.

  • For Q4 2025, Interest Expenses rose 17.63% year-over-year to $2.2 million; the TTM value through Dec 2025 reached $9.0 million, down 42.76%, while the annual FY2025 figure was $9.0 million, 16.14% down from the prior year.
  • Interest Expenses for Q4 2025 was $2.2 million at Coherus Oncology, down from $2.3 million in the prior quarter.
  • Across five years, Interest Expenses topped out at $10.6 million in Q4 2023 and bottomed at $637000.0 in Q3 2021.
  • The 5-year median for Interest Expenses is $5.7 million (2021), against an average of $5.8 million.
  • The largest annual shift saw Interest Expenses crashed 88.74% in 2021 before it surged 1083.67% in 2022.
  • A 5-year view of Interest Expenses shows it stood at $5.8 million in 2021, then soared by 62.01% to $9.4 million in 2022, then increased by 13.15% to $10.6 million in 2023, then tumbled by 81.99% to $1.9 million in 2024, then rose by 17.63% to $2.2 million in 2025.
  • Per Business Quant, the three most recent readings for CHRS's Interest Expenses are $2.2 million (Q4 2025), $2.3 million (Q3 2025), and $2.3 million (Q2 2025).